{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:52:00Z","timestamp":1791665520036,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtocrr.2026.101055","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:09:42Z","timestamp":1784909382000},"page":"101055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking the Platinum Standard in SCLC: A Meta-Analysis of Limited- and Extensive-Stage Disease in the Immunotherapy Era"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-5477","authenticated-orcid":false,"given":"Tomer","family":"Meirson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Ditzian Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Hanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101055_bib1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jtocrr.2026.101055_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2026.101055_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib5","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib6","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2026.0002","article-title":"NCCN Guidelines\u00ae Insights: small cell lung cancer, version 2.2026: featured updates to the NCCN Guidelines","volume":"24","author":"Ganti","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtocrr.2026.101055_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116042","article-title":"Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: a nationwide Netherlands registry study in small cell lung cancer patients (CACIS)","volume":"230","author":"Houda","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101055_bib8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37699","article-title":"Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans","volume":"5","author":"Azar","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtocrr.2026.101055_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8005","article-title":"Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)","volume":"43","author":"Gronberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib11","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtho.2022.07.063","article-title":"OA12.06 First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results","volume":"17","author":"Rudin","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG oncology\/alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/COC.0b013e31828aab2a","article-title":"Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide","volume":"38","author":"Karam","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101055_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.07.001","article-title":"Thymic radiation is associated with worse outcomes in patients with NSCLC","author":"Prudente","year":"2026","journal-title":"Ann Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:46:03Z","timestamp":1791665163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666364326001062"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101055","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking the Platinum Standard in SCLC: A Meta-Analysis of Limited- and Extensive-Stage Disease in the Immunotherapy Era","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101055"}}